Search | Clinical Trials Finder

Conditions: Ocular Inflammation and Pain After Cataract Surgery
Interventions: APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%; Drug
Lead sponsor: Formosa Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 31
States / cities: Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more

Conditions: Tourette Syndrome
Interventions: SCI-110, Placebo; Drug · Other
Lead sponsor: Neurothera Labs Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Placebo, Antidepressant Therapy (ADT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 58
States / cities: Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more

Conditions: Hypertension
Interventions: Nebivolol, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 29
States / cities: Buena Park, California • Chino, California • Long Beach, California + 19 more

Conditions: SCN8A Developmental and Epileptic Encephalopathy Syndrome
Interventions: NBI-921352, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more

Conditions: Cachexia
Interventions: Deuterated Water, Testosterone enanthate, Placebo to match testosterone enanthate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 60 Years to 75 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hemiparetic Stroke
Interventions: High-definition transcranial direct stimulation: sham, High-definition transcranial direct stimulation: optimal, Modified constraint-induced movement therapy; Device · Behavioral
Lead sponsor: Carle Foundation Hospital; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Allergy
Interventions: Placebo, Xolair; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Ileus
Interventions: Alvimopam, 300 mg Polyethylene; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: American Fork, Utah • Cedar City, Utah • Logan, Utah + 6 more

Conditions: Major Depressive Disorder (MDD)
Interventions: DT-101, Placebo; Drug
Lead sponsor: Draig Therapeutics Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 23
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 17 more

Conditions: Heart Failure, Sleep Disorders
Interventions: melatonin, placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 35 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Placebo, JNJ-38518168 (3 mg), JNJ-38518168 (10 mg), JNJ-38518168 (30 mg), Methotrexate; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: Huntsville, Alabama • Gilbert, Arizona • Covina, California + 6 more

Conditions: Healthy Volunteers
Interventions: BIIB133 (Dapirolizumab pegol), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions: BIBW 2948 BS; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 8
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 5 more

Conditions: Cardiovascular Disease
Interventions: Rimonabant, Placebo (for Rimonabant); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 55 Years and older
Enrollment: 18,695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Colitis, Ulcerative
Interventions: Vedolizumab, Adalimumab placebo, Adalimumab, Vedolizumab placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 771 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 77
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744, GSK1265744 matching placebo, Moxifloxacin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Alcohol Use Disorder
Interventions: Placebo, Glucagon-Like Peptide-1 Agonist (GLP-1), Naltrexone (oral tablets); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Havre de Grace, Maryland

Conditions: Fracture Arm, Fracture Closed of Lower End of Forearm, Unspecified, Fracture Elbow, Fracture Fixation, Fracture Fixation, Internal, Fracture Forearm, Fracture Distal Radius
Interventions: Lidocaine Infusion, Standard of Care (SOC); Drug · Other
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 3 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Interventions: Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task, SPN-810, Placebo; Diagnostic Test · Behavioral · Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 8 Years to 12 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 3
States / cities: Lakeland, Florida • Maitland, Florida • Tampa, Florida

Conditions: Prion Disease
Interventions: ION717, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Cleveland, Ohio

Conditions: Chronic Plaque Psoriasis
Interventions: alefacept, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 16 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 10
States / cities: Irvine, California • Santa Monica, California • Omaha, Nebraska + 7 more

Conditions: Stroke, Muscle Spasticity
Interventions: Botulinum Toxin Type A, Placebo; Biological
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy
Interventions: Synaquell, Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 13 Years to 19 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

SCI-110 in the Treatment of Tourette Syndrome

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers

Optimal Targeted High-definition Transcranial Direct Current Stimulation for Reducing Post-stroke Upper Limb Motor Impairments

The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils

Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

Melatonin Supplementation to Improve Sleep in Patients With Heart Failure

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

Combination Therapy for Alcohol Use Disorder

A Clinical Trial on the Use of Lidocaine Infusion During Surgery for Pediatric Upper Extremity Fractures and Its Impact on Total Perioperative Opioid Requirements

Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD

PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717

A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate

Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment

The Effects of Synaquell on Brain Function of Ice Hockey Players